
Heska Corporation HSKA
Quarterly report 2023-Q1
added 05-05-2023
Heska Corporation Accounts Payables 2011-2026 | HSKA
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Heska Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.4 M | 15.4 M | 15.1 M | 6.6 M | 7.47 M | 9.49 M | 6.34 M | 7.62 M | 4.9 M | 4.45 M | 5.3 M | 4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.4 M | 4 M | 8.59 M |
Quarterly Accounts Payables Heska Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.2 M | 16.4 M | 14.7 M | 12 M | 12.4 M | 15.4 M | 12.1 M | 14.6 M | 15 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 7.47 M | 7.47 M | 7.47 M | 7.47 M | 9.49 M | 9.49 M | 9.49 M | 9.49 M | 6.34 M | 7.15 M | 7.15 M | 7.15 M | 7.62 M | 7.62 M | 7.62 M | 7.62 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.45 M | 4.45 M | 4.45 M | 4.45 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 4 M | 4 M | 4 M | 4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.4 M | 4 M | 8.42 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
446 M | $ 110.31 | -2.79 % | $ 33.5 B | ||
|
Waters Corporation
WAT
|
104 M | $ 289.46 | -3.69 % | $ 17.2 B | ||
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
176 M | - | - | $ 19.8 B | ||
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Sotera Health Company
SHC
|
78 M | $ 13.12 | -3.14 % | $ 3.73 B | ||
|
Check-Cap Ltd.
CHEK
|
952 K | - | - | $ 9.42 M | ||
|
BioNano Genomics
BNGO
|
5.59 M | $ 1.15 | -0.43 % | $ 6.26 M | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
881 K | - | -6.19 % | $ 10.5 M | ||
|
DexCom
DXCM
|
344 M | $ 62.39 | -5.61 % | $ 24.3 B | ||
|
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | ||
|
Castle Biosciences
CSTL
|
6.9 M | $ 23.59 | -4.49 % | $ 655 M | ||
|
Charles River Laboratories International
CRL
|
149 M | $ 158.5 | -4.02 % | $ 7.86 B | ||
|
Quest Diagnostics Incorporated
DGX
|
307 M | $ 195.05 | -1.56 % | $ 21.7 B | ||
|
Organovo Holdings
ONVO
|
1.64 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
245 K | - | -16.95 % | $ 1.54 M | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
PerkinElmer
PKI
|
185 M | - | -0.91 % | $ 14.7 B | ||
|
Invitae Corporation
NVTA
|
14 M | - | - | $ 21.2 M | ||
|
Interpace Biosciences
IDXG
|
1.66 M | $ 1.68 | -2.89 % | $ 7.37 M | ||
|
QIAGEN N.V.
QGEN
|
83.3 M | - | - | $ 10.6 B | ||
|
Neogen Corporation
NEOG
|
79.6 M | $ 8.71 | -4.86 % | $ 1.89 B | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
841 M | $ 264.08 | -1.6 % | $ 22 B | ||
|
Psychemedics Corporation
PMD
|
752 K | - | -1.84 % | $ 15.3 M | ||
|
Precipio
PRPO
|
622 K | $ 25.69 | -5.55 % | $ 33.3 M | ||
|
CareDx, Inc
CDNA
|
9.99 M | $ 16.68 | -4.55 % | $ 889 M | ||
|
Quotient Limited
QTNT
|
4.66 M | - | -11.32 % | $ 1.1 M | ||
|
Syneos Health
SYNH
|
108 M | - | - | $ 4.46 B | ||
|
Renalytix AI plc
RNLX
|
1.4 M | - | 5.66 % | $ 22.7 M | ||
|
VolitionRx Limited
VNRX
|
2.77 M | $ 0.19 | -0.08 % | $ 18.3 M | ||
|
Biodesix
BDSX
|
2.19 M | $ 14.29 | -2.16 % | $ 1.85 B | ||
|
Celcuity
CELC
|
6.41 M | $ 108.63 | -5.38 % | $ 5.08 B | ||
|
Biomerica
BMRA
|
295 K | $ 1.99 | -5.52 % | $ 4.57 M | ||
|
Burning Rock Biotech Limited
BNR
|
63.1 M | $ 16.61 | -10.22 % | $ 179 M | ||
|
Bioventus
BVS
|
10.9 M | $ 8.93 | -3.62 % | $ 595 M | ||
|
Co-Diagnostics
CODX
|
1.48 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Meridian Bioscience
VIVO
|
17.8 M | - | - | $ 1.49 B |